Analyst upgrades:

• Baird upgraded Tenet Healthcare (NYSE: THC) to Outperform from Neutral and raised its target to $6 from $5 based on cost trends, valuation, and expectations the company can beat expectations over the next six months.
• Oppenheimer upgraded E-House (NYSE: EJ) to Outperform from Perform following the company's better-than-expected Q2 results. The firm has a price target of $27 on shares.
• JPMorgan upgraded Avery Dennison (NYSE: AVY) to Overweight from Neutral and has a $33 target on the stock. The firm cites valuation for the upgrade following the recent underperformance and expects the company's margins to expand as demand rebounds.
• Citigroup (NYSE: C) was upgraded to Buy from Underperform at BofA/Merrill.
• Taubman Centers (NYSE: TCO) was upgraded to Conviction Buy from Buy at Goldman.
• First Niagara (NASDAQ: FNFG) was upgraded to Buy from Neutral at Janney Montgomery.

Analyst upgrades:

• Jefferies upgraded MDS Inc. (NYSE: MDZ) to Buy from Hold on valuation as it believes shares are pricing in a "worst case" scenario at current levels. The firm keeps a $6.50 target on the stock.
  
• JP Morgan upgraded Continental (NYSE: CAL) to Overweight from Neutral on valuation as it believes the recent sell-off is overdone. The firm keeps a $13 price target on the stock.
• Thomas Weisel is positive on Allergan's (NYSE: AGN) diverse product portfolio, global infrastructure, vertical integration, and deep pipeline. The firm upgraded shares to Overweight from Market Weight and has a $54 target on the stock.
• NetLogic (NASDAQ: NETL) was upgraded to Buy from Neutral at Piper.
  
• Dover (NYSE: DOV) was raised to Buy from Neutral at Banc of America/Merrill.
  
• Map Pharmaceuticals (NASDAQ: MAPP) was upgraded at Argus to Hold from Sell.

MOST NOTEWORTHY: Taubman Centers, AstraZeneca and Blue Nile were today's noteworthy initiations:

• Friedman Billings believes Taubman Centers (NYSE: TCO) is very well positioned with its upscale regional malls and lifestyle centers to weather the current challenges in the current retail environment. Shares were assumed with an Outperform rating and $64 target.
  
• JP Morgan initiated AstraZeneca (NYSE: AZN) with a Neutral rating. The firm expects investor confidence in the coming months to improve as expectations are AZN's pipeline is low.
  
• Deutsche Bank finds Blue Nile (NASDAQ: NILE) fairly valued given the challenging economic environment and rising commodity prices and initiated shares with a Hold rating and $48 target.

OTHER INITIATIONS:

• Wachovia started American Water Works (NYSE: AWK) with a Market Perform rating.
  
• Heartland Payment (NYSE: HPY) was assumed with a Buy rating and $33 target at Citigroup.
  
• Goldman resumed coverage of AbitibiBowater (NYSE: ABH) with a Neutral rating.